BBIO vs ERAS
BBIO: BridgeBio is a portfolio-based biotech firm focused on translating genetic science into precision therapies for patients with severe genetic disorders. ERAS: Erasca is a precision oncology company dedicated to shutting down the RAS/MAPK pathway to effectively treat patients with cancer.
Side-by-side fundamentals
| Metric | BBIO | ERAS | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $65.04 | $15.46 | |
| Market cap | $12.7B | $5.4B | |
| Net margin FY2025, SEC XBRL | -146.0% | n/a | |
| Operating margin FY2025, SEC XBRL | -104.2% | n/a | |
| ROE FY2025, SEC XBRL | n/a | -38.3% | |
| ROA FY2025, SEC XBRL | -78.3% | -31.4% | ERAS higher |
| Debt / equity as of 2026-09-03 | 8.27 | 0.00 | ERAS lower |
| Revenue growth (YoY) as of 2026-09-03 | +355.2% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +86.3% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.06 | 1.33 | |
| 1-year return as of 2026-10-08 close | +17.6% | +536.2% | ERAS higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.